172 related articles for article (PubMed ID: 18644960)
21. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
[TBL] [Abstract][Full Text] [Related]
22. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
[TBL] [Abstract][Full Text] [Related]
23. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
Al-Dossary FS; Ong LT; Correa AG; Starke JR
Pediatr Infect Dis J; 2002 Feb; 21(2):91-7. PubMed ID: 11840073
[TBL] [Abstract][Full Text] [Related]
24. [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].
Lounis N; Guillemont J; Veziris N; Koul A; Jarlier V; Andries K
Med Mal Infect; 2010 Jul; 40(7):383-90. PubMed ID: 19954909
[TBL] [Abstract][Full Text] [Related]
25. [Bactericidal therapy in patients with tuberculosis].
Krasnov VA; Ursov IG
Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
[No Abstract] [Full Text] [Related]
26. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
27. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
Ul-Ain Q; Sharma S; Khuller GK
Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
[TBL] [Abstract][Full Text] [Related]
29. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
30. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
[TBL] [Abstract][Full Text] [Related]
31. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
Lambert LA; Ijaz K; Navin TR
Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
[No Abstract] [Full Text] [Related]
32. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
33. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
34. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Srivastava S; Deshpande D; Magombedze G; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
[TBL] [Abstract][Full Text] [Related]
35. [Short-course chemotherapy of tuberculosis with pyrazinamide].
Asai S; Futsuki Y; Tomari S; Araki J
Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
[TBL] [Abstract][Full Text] [Related]
36. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.
Hoff DR; Caraway ML; Brooks EJ; Driver ER; Ryan GJ; Peloquin CA; Orme IM; Basaraba RJ; Lenaerts AJ
Antimicrob Agents Chemother; 2008 Nov; 52(11):4137-40. PubMed ID: 18694944
[TBL] [Abstract][Full Text] [Related]
37. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Daniel N; Lounis N; Ji B; O'Brien RJ; Vernon A; Geiter LJ; Szpytma M; Truffot-Pernot C; Hejblum G; Grosset J
Am J Respir Crit Care Med; 2000 May; 161(5):1572-7. PubMed ID: 10806157
[TBL] [Abstract][Full Text] [Related]
38. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Boeree MJ; Diacon AH; Dawson R; Narunsky K; du Bois J; Venter A; Phillips PP; Gillespie SH; McHugh TD; Hoelscher M; Heinrich N; Rehal S; van Soolingen D; van Ingen J; Magis-Escurra C; Burger D; Plemper van Balen G; Aarnoutse RE;
Am J Respir Crit Care Med; 2015 May; 191(9):1058-65. PubMed ID: 25654354
[TBL] [Abstract][Full Text] [Related]
39. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
